HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.

May 10, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics maintains a Buy rating and a $9 price target from HC Wainwright & Co., indicating a positive outlook from the analyst.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong vote of confidence in Regulus Therapeutics. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term, especially if the market perceives this as a signal of underlying value and future growth prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100